MCSeres Therapeutics, Inc. MCRB · NASDAQ
$1.98 -6.60% (-$0.14)
- Market cap
- $19.7M
- Enterprise value
- $60.7M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 10.5x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -90.0%
- Gross margin
- 82.6%
- Net margin
- -1,192.9%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.22
- Free float
- 76.4%
About the company
Seres Therapeutics, Inc. (MCRB) is a biotechnology company focused on developing microbiome-based therapies. Their research and development efforts are centered around leveraging natural bacterial communities inhabiting the human body to treat various diseases. Seres Therapeutics particularly targets areas of the gastrointestinal tract, infectious diseases, and immune disorders. The company is developing microbiome-based therapeutics aimed at restoring the health of microbial communities in patients. Their research focuses on identifying and selecting appropriate bacterial strains and their application in treating specific diseases. Shares of Seres Therapeutics, Inc. (MCRB) could be suitable for investors seeking investments in the biotechnology sector with a focus on developing innovative microbiome-based drugs.
Sector
Healthcare
Industry
Biotechnology
CEO
Richard N. Kender
Employees
66
Headquarters
Cambridge
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What to watch: It missed profit estimates 4 times in the last 8 quarters.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What to watch: It passes only 3 of the 9 points of the Piotroski financial health test.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
- What speaks for it: The price moves less than the market (beta 0.22).
Statements
Every number